(Q31155491)

21 August 2017

Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial (English)

1 reference

21 August 2017

0 references

1 reference

placebo-controlled trial

1 reference

non-alcoholic steatohepatitis

inferred from title

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Tisha R Joy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Charles A McKenzie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Rommel G Tirona

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kelly Summers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Shannon Seney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Neel Malhotra

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Melanie D Beaton

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 January 2017

1 reference

World Journal of Gastroenterology

21 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

141-150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

10 June 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5221278/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Pharmacology, physiology, and mechanisms of incretin hormone action

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Evaluation of adipose tissue volume quantification with IDEAL fat-water separation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Liver diseases and diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

The global NAFLD epidemic

21 June 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V23.I1.141

Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

Dipeptidyl peptidase IV (DDP IV) in NASH patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5221278

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

31 October 2018

1 reference

12 December 2020

Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice

1 reference

12 December 2020

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus

1 reference

12 December 2020

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats

1 reference

12 December 2020

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V23.I1.141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28104990%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

28104990

1 reference